Related Experiment Video
Updated: May 13, 2026
05:55
Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
Published on: December 1, 2023
Treating multiple sclerosis with monoclonal antibodies: a 2013 update
Annika Deiß1, Isabel Brecht, Axel Haarmann
1Department of Neurology, University of Würzburg, Josef-Schneider-Str 11, Würzburg 97080, Germany.
Expert Review of Neurotherapeutics
|March 2, 2013
Summary
This review covers monoclonal antibody treatments for multiple sclerosis (MS) from 2010-2012, detailing natalizumab, alemtuzumab, and anti-CD20 therapies. It examines emerging treatments and their future role in MS management.
Area of Science:
- Immunology
- Neurology
- Pharmacology
Background:
- Monoclonal antibodies represent a significant advancement in multiple sclerosis (MS) treatment.
- The period 2010-2012 saw continued development and evaluation of various antibody-based therapies for MS.
Purpose of the Study:
- To provide an in-depth review of monoclonal antibody treatments for MS between 2010 and 2012.
- To update on natalizumab, alemtuzumab, daclizumab, and anti-CD20 antibodies (ocrelizumab, ofatumumab).
- To discuss emerging antibody therapies and their potential role in the future MS therapeutic landscape.
Main Methods:
- Literature review of clinical trial results and immunological data published between 2010-2012.
- Critical analysis of Phase II and III trial outcomes for various monoclonal antibodies.
- Evaluation of safety profiles, including progressive multifocal leukoencephalopathy (PML) associated with natalizumab.
Main Results:
- Natalizumab use requires careful monitoring for PML and management of cessation effects; its dual pro-inflammatory and anti-inflammatory actions are noted.
- Alemtuzumab shows promise but requires careful patient selection and consideration of long-term immunological impact.
- Anti-CD20 antibodies like ocrelizumab and ofatumumab demonstrate efficacy, with ongoing trials for daclizumab. Emerging therapies targeting IL-17A and other targets are also under investigation.
Conclusions:
- Monoclonal antibodies are a cornerstone of modern MS therapy, with ongoing innovation and expanding treatment options.
- Understanding the specific mechanisms, risks, and benefits of each antibody is crucial for optimal patient management.
- The medium-term therapeutic armamentarium for MS will likely include a diverse range of monoclonal antibodies with distinct targets and effects.
More Related Videos
11:10Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
Published on: June 29, 2016
06:19Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:19Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...